Actively Recruiting
Effect of the Metacognitive Training Programme (D-MCT) for Women With Peripartum Depression
Led by CHU de Reims · Updated on 2026-02-20
96
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate the effects of a metacognitive training program called D-MCT on women experiencing peripartum depression (PPD), a condition that can occur during pregnancy or within 12 months after childbirth. PPD affects 10 to 20% of new mothers and can cause difficulties in mother-child interactions and lasting consequences for both mother and child. The study seeks to demonstrate whether D-MCT reduces depressive symptoms and improves metacognitive functioning more than usual care. Participants will be randomly assigned to either the D-MCT group, which receives this brief group metacognitive therapy designed to reduce cognitive biases and improve self-regulation, or a control group receiving usual management techniques. The therapy is easy to follow and has shown promise in prior studies for reducing symptoms of depression and anxiety. The study also aims to assess the impact of D-MCT on the mother-child bonding quality. Women participating will undergo assessments including the Edinburgh Postnatal Depression Scale at three months to measure depressive symptoms. The study will monitor changes in depression and mother-child interactions over time, with support available for infant care during group sessions if needed. The total participation duration extends through the treatment and follow-up periods to evaluate both symptom changes and bonding quality.
CONDITIONS
Brief Title
New Cognitive Treatment for Peripartum Depression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women over 18 years old
- Diagnosed with depressive disorder with peripartum onset and have already given birth
- Edinburgh Postnatal Depression Scale (EPDS) score over 10
- Provided consent to participate
- Affiliated with a social security system
- Adequate knowledge of written, spoken, and understood French (mother tongue or primary French education)
You will not qualify if you...
- Under legal protection measures
- Under 18 years old
- Diagnosed with schizophrenia spectrum disorders
- Substance abuse or dependence (alcohol, drugs)
- Insufficient command of the French language
- Having a deceased child
- Not meeting diagnostic criteria for depressive disorder with peripartum onset
- Declined to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 months
Participants receive metacognitive training therapy or usual management techniques to reduce symptoms of peripartum depression and anxiety.
Weekly visits during treatment period
Duration - 3 months post-treatment
Participants are monitored to assess the impact of the treatment on depressive symptoms and mother-child attachment after therapy ends.
1 visit at 3 months post-treatment
Trial Site Locations
Total: 1 location
1
Chu Reims
Reims, France, 51092
Actively Recruiting
Research Team
A
Anne Catherine ROLLAND
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here